drospirenone has been researched along with Hemorrhage, Uterine in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (26.67) | 29.6817 |
| 2010's | 7 (46.67) | 24.3611 |
| 2020's | 4 (26.67) | 2.80 |
| Authors | Studies |
|---|---|
| Achilles, SL; Apolikhina, I; Bouchard, C; Chen, MJ; Creinin, MD; Foidart, JM; Jensen, JT; Jost, M; Kaunitz, AM; Piltonen, T; Suturina, L; Westhoff, CL; Weyers, S; Zatik, J | 1 |
| Apter, D; Colli, E; Gemzell-Danielsson, K; Peters, K | 1 |
| Colli, E; Palacios, S; Regidor, PA | 2 |
| Apter, D; Beekman, L; Coelingh Bennink, HJT; Foidart, JM; Maillard, C; Mawet, M; Zimmerman, Y | 1 |
| Genazzani, AR; Gerlinger, C; Gude, K; Schaefers, M; Schmelter, T | 1 |
| Baihua, D; Caiyan, W; Hongyu, W; Huan, S; Liangdan, T; Meiqing, X; Mulan, R; Qinping, L; Shulan, Z; Wen, D; Xiaomao, L; Xiaoyan, X; Youdi, X; Yufeng, L; Zheng'ai, X; Zhisong, M; Zirong, H; Ziyan, H | 1 |
| Ahrendt, HJ; Archer, DF; Drouin, D | 1 |
| Cheng, J; Zhang, Z | 1 |
| Athayde, C; Casoy, J; Coutinho, EM; Maia, H; Valente Filho, J | 1 |
| Cremer, M; Jacobs, A; Phan-Weston, S | 1 |
| Bachmann, G; Benda, N; Marr, J; Sampson-Landers, C; Sulak, PJ | 1 |
| Brown, C; Foegh, M; Pearlstein, TB; Rapkin, A; Sampson-Landers, C; Yonkers, KA | 1 |
| Foidart, JM; Schellschmidt, I; Sulak, PJ; Zimmermann, D | 1 |
| Parsey, KS; Pong, A | 1 |
1 review(s) available for drospirenone and Hemorrhage, Uterine
| Article | Year |
|---|---|
Recent innovations in oral contraception.
Topics: Acne Vulgaris; Androstenes; Contraception; Contraceptives, Oral, Hormonal; Endometrial Hyperplasia; Estradiol; Ethinyl Estradiol; Female; Hirsutism; Humans; Hyperkalemia; Levonorgestrel; Menstrual Cycle; Menstruation Disturbances; Ovulation; Pregnancy; Randomized Controlled Trials as Topic; Thromboembolism; Uterine Hemorrhage | 2010 |
10 trial(s) available for drospirenone and Hemorrhage, Uterine
| Article | Year |
|---|---|
Pooled analysis of two phase 3 trials evaluating the effects of a novel combined oral contraceptive containing estetrol/drospirenone on bleeding patterns in healthy women.
Topics: Adolescent; Adult; Androstenes; Contraceptives, Oral, Combined; Estetrol; Estrogens; Female; Humans; Metrorrhagia; Middle Aged; Uterine Hemorrhage; Young Adult | 2022 |
Multicenter, open-label trial to assess the safety and tolerability of drospirenone 4.0 mg over 6 cycles in female adolescents, with a 7-cycle extension phase.
Topics: Adolescent; Androstenes; Contraceptives, Oral; Dysmenorrhea; Female; Humans; Menstrual Cycle; Uterine Hemorrhage | 2020 |
Bleeding profile of women using a drospirenone-only pill 4 mg over nine cycles in comparison with desogestrel 0.075 mg.
Topics: Adolescent; Adult; Androstenes; Contraceptives, Oral, Combined; Desogestrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Middle Aged; Placebo Effect; Uterine Hemorrhage; Young Adult | 2020 |
Overall and bleeding-related discontinuation rates of a new oral contraceptive containing 4 mg drospirenone only in a 24/4 regimen and comparison to 0.075 mg desogestrel.
Topics: Adult; Androstenes; Contraceptives, Oral, Hormonal; Desogestrel; Double-Blind Method; Female; Humans; Medication Adherence; Mineralocorticoid Receptor Antagonists; Prospective Studies; Uterine Hemorrhage | 2021 |
Estetrol combined with drospirenone: an oral contraceptive with high acceptability, user satisfaction, well-being and favourable body weight control.
Topics: Adolescent; Adult; Androstenes; Body Weight; Contraceptives, Oral, Combined; Contraceptives, Oral, Hormonal; Estetrol; Female; Finland; Humans; Intention to Treat Analysis; Mineralocorticoid Receptor Antagonists; Patient Satisfaction; Surveys and Questionnaires; Uterine Hemorrhage; Young Adult | 2017 |
One-year randomized study of the endometrial safety and bleeding pattern of 0.25 mg drospirenone/0.5 mg 17β-estradiol in postmenopausal women.
Topics: Adult; Aged; Androstenes; Biopsy; Double-Blind Method; Drug Therapy, Combination; Endometrial Hyperplasia; Endometrium; Estradiol; Estrogen Replacement Therapy; Female; Humans; Middle Aged; Postmenopause; Treatment Outcome; Uterine Hemorrhage | 2013 |
Drospirenone-only oral contraceptive: results from a multicenter noncomparative trial of efficacy, safety and tolerability.
Topics: Adolescent; Adult; Androstenes; Contraception; Contraceptives, Oral, Hormonal; Europe; Female; Healthy Volunteers; Humans; Menstrual Cycle; Menstruation Disturbances; Middle Aged; Mineralocorticoid Receptor Antagonists; Pregnancy; Prospective Studies; Uterine Hemorrhage; Young Adult | 2015 |
Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3 mg drospirenone.
Topics: Adolescent; Adult; Androstenes; Contraceptives, Oral, Combined; Estrogens; Ethinyl Estradiol; Female; Headache; Humans; Patient Compliance; Patient Satisfaction; Pregnancy; Progesterone Congeners; Uterine Hemorrhage | 2004 |
Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder.
Topics: Adult; Androstenes; Contraceptives, Oral, Combined; Contraceptives, Oral, Hormonal; Double-Blind Method; Estrogens; Ethinyl Estradiol; Female; Humans; Premenstrual Syndrome; Progesterone Congeners; Quality of Life; Treatment Outcome; Uterine Hemorrhage | 2005 |
The use of an oral contraceptive containing ethinylestradiol and drospirenone in an extended regimen over 126 days.
Topics: Adult; Androstenes; Contraceptives, Oral; Ethinyl Estradiol; Female; Humans; Menstrual Cycle; Patient Satisfaction; Prospective Studies; Time Factors; Uterine Hemorrhage | 2006 |
4 other study(ies) available for drospirenone and Hemorrhage, Uterine
| Article | Year |
|---|---|
[Efficacy and safety of a combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 µg in a 24+4-day regimen in China].
Topics: Adolescent; Adult; Androstenes; Body Weight; China; Contraceptives, Oral, Combined; Dose-Response Relationship, Drug; Drug Administration Schedule; Estrogens; Ethinyl Estradiol; Female; Humans; Menstrual Cycle; Menstruation; Mineralocorticoid Receptor Antagonists; Pregnancy; Pregnancy Rate; Treatment Outcome; Uterine Hemorrhage; Young Adult | 2014 |
[Clinical and metabolic effects of drospirenone-estradiol versus tibolone in postmenopausal women:a comparative study].
Topics: Androstenes; Drug Combinations; Estradiol; Estrogen Receptor Modulators; Female; Humans; Norpregnenes; Postmenopause; Retrospective Studies; Uterine Hemorrhage | 2015 |
The effect of a continuous regimen of drospirenone 3 mg/ethinylestradiol 30 microg on Cox-2 and Ki-67 expression in the endometrium.
Topics: Adult; Androstenes; Contraceptives, Oral, Synthetic; Cyclooxygenase 2; Dose-Response Relationship, Drug; Endometrium; Estrogens; Ethinyl Estradiol; Female; Humans; Ki-67 Antigen; Mineralocorticoid Receptor Antagonists; Observation; Uterine Hemorrhage | 2010 |
An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen.
Topics: Adolescent; Adult; Androstenes; Blood Pressure; Body Weight; Contraceptives, Oral, Combined; Contraceptives, Oral, Hormonal; Ethinyl Estradiol; Female; Humans; Lipids; Menstruation Disturbances; Mineralocorticoid Receptor Antagonists; Patient Compliance; Progesterone Congeners; Surveys and Questionnaires; Uterine Hemorrhage | 2000 |